Search research articles
Contact Us
Filters
Showing results (111-120 of 144) with videos related to
Page
of 15
Sort By:
Eclinicalmedicine
|
October 29, 2024
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
Nicola L Brice, Mark Carlton, David H Margolin, et al.
Archives of Gerontology and Geriatrics
|
June 29, 2007
Prevalence of movement disorders in an elderly nursing home population
Winona Tse, Leslie S Libow, Richard Neufeld, et al.
Journal of Parkinson'S Disease
|
November 9, 2020
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study
C Warren Olanow, Alberto J Espay, Fabrizio Stocchi, et al.
The Lancet. Neurology
|
July 11, 2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
Robert A Hauser, C Warren Olanow, Karl D Kieburtz, et al.
The Lancet. Neurology
|
June 8, 2015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay, Mathieu Bourdenx, Philippe Gorry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 27, 2023
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease
C Warren Olanow, Robert A Hauser, Daniel J Burdick, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 3, 2024
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study
C Warren Olanow, Deborah McIntyre, Michele Matarazzo, et al.
Neurology
|
April 12, 2013
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T Bartus, Tiffany L Baumann, Joao Siffert, et al.
The Lancet. Neurology
|
December 11, 2019
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
C Warren Olanow, Stewart A Factor, Alberto J Espay, et al.
The Lancet. Neurology
|
April 16, 2013
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities
Daniela Berg, Anthony E Lang, Ronald B Postuma, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 144) with videos related to
Sort By:
Page
of 15
Eclinicalmedicine
|
October 29, 2024
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
Nicola L Brice, Mark Carlton, David H Margolin, et al.
Archives of Gerontology and Geriatrics
|
June 29, 2007
Prevalence of movement disorders in an elderly nursing home population
Winona Tse, Leslie S Libow, Richard Neufeld, et al.
Journal of Parkinson'S Disease
|
November 9, 2020
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study
C Warren Olanow, Alberto J Espay, Fabrizio Stocchi, et al.
The Lancet. Neurology
|
July 11, 2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
Robert A Hauser, C Warren Olanow, Karl D Kieburtz, et al.
The Lancet. Neurology
|
June 8, 2015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay, Mathieu Bourdenx, Philippe Gorry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 27, 2023
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease
C Warren Olanow, Robert A Hauser, Daniel J Burdick, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 3, 2024
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study
C Warren Olanow, Deborah McIntyre, Michele Matarazzo, et al.
Neurology
|
April 12, 2013
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T Bartus, Tiffany L Baumann, Joao Siffert, et al.
The Lancet. Neurology
|
December 11, 2019
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
C Warren Olanow, Stewart A Factor, Alberto J Espay, et al.
The Lancet. Neurology
|
April 16, 2013
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities
Daniela Berg, Anthony E Lang, Ronald B Postuma, et al.
Page
of 15